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Role of Rho-Kinase in the Pathogenesis
of Coronary Hyperconstricting Responses
Induced by Drug-Eluting Stents in Pigs In Vivo
Takashi Shiroto, MD,* Satoshi Yasuda, MD, PHD,* Ryuji Tsuburaya, MD,* Yoshitaka Ito, MD,*
Jun Takahashi, MD, PHD,* Kenta Ito, MD, PHD,* Hatsue Ishibashi-Ueda, MD, PHD,†
Hiroaki Shimokawa, MD, PHD*
Sendai and Osaka, Japan
Objectives This study examined whether the Rho-kinase pathway is involved in the pathogenesis of coronary hyperconstrict-
ing responses induced by drug-eluting stents (DES) in pigs in vivo.
Background Recent studies showed that coronary vasoconstricting responses are enhanced at the edge of coronary seg-
ments implanted with DES compared with bare-metal stents (BMS) in humans. We have previously shown that
the activated Rho-kinase pathway plays a central role in the molecular mechanism of coronary vasospasm in
animals and humans.
Methods Human coronary artery smooth muscle cells (hCASMCs) were coincubated with various concentrations of pacli-
taxel (109 to 106 mol/l, corresponding levels reported in DES-implanted arterial tissue) for 24 h. A paclitaxel-
eluting stent (PES), sirolimus-eluting stent (SES), and BMS were randomly implanted in the left coronary arteries
in pigs for 4 weeks.
Results In hCASMCs, paclitaxel significantly enhanced Rho-kinase expression and activity. In a porcine model, coronary
vasoconstricting responses to serotonin (10 and 100 g/kg intracoronary administration) were significantly en-
hanced at the PES site compared with the BMS site (45  4% vs. 30  3%; p  0.01; n  12 each), and were
abolished by hydroxyfasudil (90 and 300 g/kg intracoronary administration), a selective Rho-kinase inhibitor.
The PES enhanced inflammatory responses and microthrombus formation at the stent edge, where immunore-
activities for Rho-kinase expression and activity were increased. In organ chamber experiments, serotonin-
induced contractions were significantly enhanced in rings from the PES edge site compared with the BMS edge
site. The SES also caused similar coronary hyperconstricting responses to serotonin in vivo.
Conclusions These results suggest that the Rho-kinase pathway plays an important role in the pathogenesis of DES-induced
coronary hyperconstricting responses. (J Am Coll Cardiol 2009;54:2321–9) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.045n
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Grug-eluting stents (DES) have dramatically reduced the
ate of restenosis after percutaneous coronary intervention,
evolutionizing interventional cardiology (1,2). However,
ES have also been shown not to improve patient survival
ompared with bare-metal stents (BMS) (3). Indeed, recent
tudies suggest that the early benefits of DES are offset by
n increased risk of late stent thrombosis, a potentially fatal
omplication (4). The DES-induced impairment of coro-
rom the *Department of Cardiovascular Medicine, Tohoku University Graduate
chool of Medicine, Sendai, Japan; and the †Department of Pathology, National
ardiovascular Center, Suita, Osaka, Japan. Supported in part by grants-in-aid from
he scientific research and the global Centers of Excellence project from the Japanese
inistry of Education, Culture, Sports, Science, and Technology, Tokyo, Japan.k
Manuscript received April 13, 2009; revised manuscript received June 12, 2009,
ccepted July 1, 2009.ary vasomotion is another concern regarding the long-term
afety of DES (5–10). Enhanced vasoconstriction in re-
ponse to acetylcholine (5–8) or exercise (9) was shown in
he coronary segments adjacent to DES, but not in those
djacent to BMS, and even death was reported among
atients with severe coronary vasospasm after DES implan-
ation (10). However, the underlying molecular mechanism
or the DES-induced coronary hyperconstriction remains to
e elucidated.
See page 2330
Rho-kinase is one of the down-stream effectors of the small
TP-binding protein Rho and consists of 2 isoforms, Rho-inase beta (ROCK1) and Rho-kinase alpha (ROCK2)
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Coronary Hyperconstriction and DES-Enhanced Rho-Kinase December 8, 2009:2321–9(11,12). We have previously
shown that activation of Rho-
kinase plays a central role in the
molecular mechanism of coronary
vasospasm through vascular
smooth muscle cell (VSMC)
hypercontraction and down-
regulation of endothelial nitric
oxide synthase in endothelial cells
(13–21).
In the present study, we thus
examined whether the Rho-kinase
pathway is also involved in the
pathogenesis of DES-induced
coronary hyperconstriction.
Methods
All procedures were performed
according to the protocols ap-
proved by the Institutional Com-
mittee for Use and Care of Lab-
oratory Animals of Tohoku
University (20MdA-47).
Cell culture. Human coro-
nary artery smooth muscle cells
hCASMCs) (Lonza, Walkersville, Maryland; passages 4
hrough 10) were seeded in a growth medium (SmGM-2
ullet Kit, Lonza) for 24 h and then growth-arrested in a
ulbecco modified Eagle medium (Sigma Aldrich, St. Louis,
issouri) supplemented with 0.1% bovine serum albumin, 100
U/ml penicillin, and 100 g/ml streptomycin for 24 h, and
sed for the experiments.
eal-time polymerase chain reaction for ROCK1 and
OCK2 messenger ribonucleic acid (RNA) expression.
he hCASMCs (1  105) were coincubated with 109 to
06 mol/l paclitaxel for 24 h (n  9) (22). Cells were lysed,
nd total RNA was extracted using the RNeasy Micro Kit
Qiagen, Hilden, Germany). Total RNA (600 ng) was reverse-
ranscribed using a QuantiTect Reverse Transcription Kit
Qiagen). Real-time polymerase chain reaction was performed
sing the Real-Time Detection System (Bio-Rad Laboratories,
ercules, California). Sequences of the primers were (forward,
everse) 5=-CTGCAACTGGAACTCAACCAAGAA-3=, 5=-
TAGCACGCAATTGCTCAATATCAC-3= for ROCK1,
=-TGCTTTAAATTTGCTGGCTACCCTA-3=, 5=-
ACACAGCTGCATGTCTGAGGA-3= for ROCK2, and
=-TGGCACCCAGCACAATGAA-3=, 5=-CTAAGTC-
TAGTCCGCCTAGAAGCA-3= for beta-actin, all of
hich were designed by the Perfect Real Time Support System
Takara Bio Inc., Shiga, Japan). The beta-actin was used as an
nternal control; SYBR Premix Ex Taq I and II (Takara Bio
nc.) were used for the detection of ROCK1 and ROCK2
DNA, respectively.
estern blotting for Rho-kinase activity. The hCASMCs
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CAG  coronary
angiography
DES  drug-eluting stent(s)
ERM  ezrin/radixin/
moesin
hCASMC  human
coronary artery smooth
muscle cell
IC  intracoronary
administration
MYPT1  myosin
phosphatase target subunit 1
PES  paclitaxel-eluting
stent(s)
RNA  ribonucleic acid
ROCK1  Rho-kinase beta
ROCK2  Rho-kinase alpha
SES  sirolimus-eluting
stent(s)
VSMC  vascular smooth
muscle cell1  105) were coincubated with 108 mol/l paclitaxel, a 2omparable concentration in the DES-implanted coronary
rteries in pigs (n  6) for 24 h (23). Western blot analysis
as performed for Rho-kinase activity, which was expressed
s the extent of phosphorylated ezrin/radixin/moesin
ERM) family, substrates of Rho-kinase, compared with
hat of total ERM, as previously reported (24).
n vivo study. Domestic male pigs (2 to 3 months old and
eighing 20 to 30 kg) were pre-treated orally with aspirin (300
g/day) and clopidogrel (150 mg/day) for 2 days before stent
mplantation. After sedation with ketamine hydrochloride (15
g/kg intramuscularly) and anesthesia with inhaled 2% to 5%
evoflurane and heparinization (5,000 U intravenously), we
andomly implanted a paclitaxel-eluting stent (PES) (Taxus
xpress 2, Boston Scientific, Natick, Massachusetts) and a
MS (Express 2, Boston Scientific) in the left anterior de-
cending and circumflex coronary arteries in the same pig (n
). In an additional experiment, another set of comparisons
etween a sirolimus-eluting stent (SES) (Cypher, Johnson &
ohnson, New Brunswick, New Jersey) and a BMS (Velocity,
ohnson & Johnson) was performed (n  6). We defined the
ontrol sites as those at 10 to 20 mm proximal and distal to the
tent edges, and calculated overstretch ratio of stent diameter
y dividing a control vessel diameter (25). The antiplatelet
herapy with aspirin and clopidogrel was continued after the
tent implantation for 4 weeks.
Four weeks after the stent implantation, we performed
oronary angiography (CAG) to examine coronary vasomotion
26). Briefly, after the baseline CAG, we examined coronary
esponses to serotonin (10 and 100 g/kg intracoronary ad-
inistration [IC]) and then to bradykinin (0.1 g/kg IC). We
e-examined the responses to serotonin after hydroxyfasudil
30 and 100 g/kg/min IC infusion for 3 min), a specific
ho-kinase inhibitor (11), then those to bradykinin after
ntracoronary infusion of NG-monomethyl-L-arginine (1
g/kg for 10 min) (27), and finally those to nitroglycerin (10
g/kg IC). We performed each protocol at a 30-min interval
26). Quantitative CAG (DFP-2000A, Toshiba Medical,
okyo, Japan) was performed in a blind manner as previously
eported (13,15). For clarity of the data, the mean value of the
asomotor responses of the proximal and the distal stent edges
s presented. In the PES protocol, 2 animals were excluded
ecause of 50% coronary restenosis (n  1) and severe
nfection (n  1).
istological analysis. After the CAG study, animals were
uthanized with a lethal dose of sodium pentobarbital (40
g/kg intravenously), and histological analysis was performed
s previously reported (28). The extent of microthrombus
ormation was assessed semiquantitatively by using the follow-
ng scale: 0  none; 1  minute thrombus peristent; 2 
hrombus 50% circular area of peristent; and 3  thrombus
ll around stent strut. The extent of inflammatory responses,
ncluding peristent leukocyte and macrophage infiltration and
dventitial inflammatory changes, was also assessed by using
he following scale: 0 none; 1 fewer than 5 inflammatory
ells; 2 fewer than 20 inflammatory cells; and 3more than
0 inflammatory cells.
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December 8, 2009:2321–9 Coronary Hyperconstriction and DES-Enhanced Rho-Kinasemmunohistological analysis. Immunohistochemical
taining was performed using mouse antihuman ROCK1
ntibody (1:50, BD Biosciences, San Jose, California),
ouse antihuman ROCK2 antibody (1:50, BD Bio-
ciences), and rabbit antihuman phosphorylated myosin
hosphatase target subunit 1 (phospho-MYPT1, Thr696)
1:50, Upstate, Billerica, Massachusetts), substrates of Rho-
inase (29). Nonimmune mouse or rabbit immunoglobulin
was used as negative control. We semiquantitatively
ssessed the extent of ROCK1, ROCK2, and phosphory-
ated MYPT1 using the following scale: 0  none; 1 
light; 2  moderate; and 3  high (30).
rgan chamber experiments. Organ chamber experiments
ere performed (n 8) at 4 weeks after the stent implantation
15,26). Briefly, the coronary segments just adjacent to the
roximal and distal edges of the stent (4-mm-long rings) were
emoved by gentle rubbing of the luminal surface with a
otton swab. The coronary segment at 20 mm distal to the
tent edge was used as a control. The contractions to
erotonin (109 to 3  106 mol/l) were examined and
ere expressed as a percentage to the average value of the
-time pre-contractions to 62 mmol/l KCl (15,26).
tatistical analysis. All results are expressed as mean 
EM. The results of reverse-transcriptase polymerase chain
eaction were analyzed by 1-way analysis of variance fol-
owed by the Dunnett test, and the dose-dependent linear
rend was also assessed. The results of Western blotting and
ngiographical data were analyzed by unpaired Student t
est. The results of organ chamber experiments were ana-
yzed by 2-way analysis of variance followed by a Bonferroni
Figure 1 Paclitaxel Increases Rho-Kinase Expression and Activ
(A) Paclitaxel significantly enhanced messenger ribonucleic acid expression of Rho
manner. *p  0.05 versus control. (B) Rho-kinase activity, as evaluated by the ex
coincubation with paclitaxel (108 mol/l). p-ERM  phosphorylated ezrin/radixin/mest. The results of histological studies and immunohisto-
wogical studies were analyzed by Mann-Whitney U test. A
alue of p  0.05 was considered to be statistically
ignificant.
esults
aclitaxel increases Rho-kinase expression and activity
n vitro. In cultured hCASMCs, paclitaxel (109 to 106
ol/l for 24 h) increased messenger RNA expression of
oth ROCK1 and ROCK2 in a concentration-dependent
anner (both p  0.0001 for linear trend) (Fig. 1A).
aclitaxel (108 mol/l for 24 h) also significantly increased
he extent of ERM phosphorylation, a marker of Rho-
inase activity (Fig. 1B).
ES induces hydroxyfasudil-sensitive coronary hyper-
onstricting responses in vivo. In the stent implantation
rocedure, there was no significant difference in the proce-
ures between the BMS and the PES sites (Table 1). Four
eeks after the stent implantation, intracoronary serotonin
Vitro
e beta (ROCK1) and Rho-kinase alpha (ROCK2) in a concentration-dependent
f ezrin/radixin/moesin phosphorylation, was significantly increased after 24-h
; t-ERM  total ezrin/radixin/moesin.
rocedural and Angiographic Findings,omparison Between BMS and PESTable 1 Procedural and Angiographic Findings,Comparison Between BMS and PES
BMS PES p Value
Control vessel diameter (mm) 2.55 0.08 2.48 0.07 0.54
Stent diameter (mm) 2.72 0.09 2.58 0.08 0.26
Stent length (mm) 16.0 0.0 16.0 0.0 N/A
Overstretch ratio 1.06 0.04 1.04 0.4 0.73
Maximum inflation pressure (atm) 10.7 1.28 8.7 0.42 0.19
alues are expressed as mean  SEM (n  6 each). Stent diameter was calculated by averaging
he diameters at the proximal edge, mid portion, and distal edge of the stented coronary artery.
verstretch ratio is the stent diameter divided by the control vessel diameter. Nominal pressureity In
-kinas
tent o
oesinas 9 atm for both BMS (Express 2, Boston Scientific, Natick, Massachusetts) and PES.
BMS  bare-metal stent(s); PES  paclitaxel-eluting stent(s); N/A  not available.
c
s
w
h
Q
e
w
(
s
b
d
(
w
(
M
t
s
v
b
2324 Shiroto et al. JACC Vol. 54, No. 24, 2009
Coronary Hyperconstriction and DES-Enhanced Rho-Kinase December 8, 2009:2321–9aused hyperconstriction at the proximal and distal edge
egments of the PES site as compared with the BMS site,
hich was abolished by intracoronary pre-treatment with
ydroxyfasudil, a selective Rho-kinase inhibitor (Fig. 2).
uantitative analysis showed that the responses of the stent
dges were significantly enhanced at the PES site compared
ith the BMS site and were abolished by hydroxyfasudil
Fig. 3A). In contrast, the vasoconstricting responses to
erotonin were comparable in the control (nonstented) sites
etween the BMS and the PES sites (Fig. 3B).
Figure 2 PES Enhances Coronary Vasoconstricting Responses
Representative left coronary angiograms under control condition (A), after intracor
hydroxyfasudil (HF) (300 g/kg intracoronary administration). The red lines indicat
of bare-metal stent (BMS) implantation. Red arrows indicate the proximal and dist
tal edge of PES and BMS are shown in the boxes (B).
Figure 3 PES Enhances Coronary Vasoconstricting Responses
Coronary vasoconstricting responses to intracoronary serotonin (5-HT) before and
vasoconstricting responses are expressed as percent changes in diameter from th
expressed as mean  SEM. *p  0.05 versus control site. †p  0.01 versus BMCoronary vasodilating responses to bradykinin did not
iffer significantly between the PES and the BMS sites
PES 1.6  1.1%, BMS 1.4  0.6% from baseline) and
ere equally impaired as compared with the control sites
PES 5.8  1.3%, BMS 6.0  0.9%, both p  0.01).
oreover, responses to bradykinin with and without pre-
reatment of NG-monomethyl-L-arginine did not differ
ignificantly between the BMS and the PES sites. Coronary
asodilating responses to nitroglycerin were comparable
etween the 2 stent sites (PES 3.5  1.4%, BMS 3.9 
s In Vivo
serotonin (100 g/kg intracoronary administration) without (B) and with (C)
ite of paclitaxel-eluting stent (PES) implantation, and blue lines indicate the site
es of PES, and blue arrows indicate those of BMS. Magnified images of the dis-
s In Vivo
e pre-treatment with HF in the stent edges (A) and the control sites (B). The
l with nitroglycerin (10 g/kg intracoronary administration). Results are
p  0.01 versus control site. Abbreviations as in Figure 2.in Pig
onary
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after th
e leve
S. **
1
(
P
i
s
w
t
p
t
s
B
P
k
R
p
t
P
o
c
w
s
c
o
t
S
t
p
w
r
r
C
n
s
i
a
m
0
B
p
D
T
c
2325JACC Vol. 54, No. 24, 2009 Shiroto et al.
December 8, 2009:2321–9 Coronary Hyperconstriction and DES-Enhanced Rho-Kinase.5%) with no significant difference with the control sites
PES 9.0  2.0%, BMS 6.9  1.2%).
ES enhances coronary microthrombus formation and
nflammatory responses in vivo. Histological analysis
howed that neointimal formation of the coronary artery
as significantly suppressed in the PES site compared with
he BMS site (Figs. 4A to 4C). However, the extent of
eristent microthrombus formation (Figs. 4D to 4F) and
hat of inflammatory responses (Figs. 4G to 4I) were
ignificantly enhanced at the PES site compared with the
MS site.
ES enhances coronary Rho-kinase expression and Rho-
inase activity. Immunohistological analysis showed that
OCK1 (Figs. 5A to 5D), ROCK2 (Figs. 5E to 5H), and
hospho-MYPT1 (Figs. 5I to 5L) were highly expressed in
he PES as compared with the BMS site.
ES enhances contractions to serotonin of isolated cor-
nary arteries. In organ chamber experiments, serotonin
aused concentration-dependent contractions of coronary rings
ithout endothelium. The extent of the contractions at the
tent edge segments was significantly greater at the PES site
ompared with the BMS site (Fig. 6A). In contrast, the extent
Figure 4 PES Enhances Coronary Microthrombus Formation an
Representative photomicrographs of BMS-treated arteries (A, D, G) and PES-treate
respectively. Semiquantitative analysis showed that although neointimal formation
(arrowheads in E, panel F) and inflammatory responses (arrowheads in H, panel
each). Abbreviations as in Figure 2.f the contractions at the control sites was comparable between
he BMS and the PES sites (Fig. 6B).
ES induces coronary hyperconstricting responses similar
o those of PES in vivo. In an additional experiment, we
erformed a similar in vivo protocol with SES to examine
hether other DES also cause coronary hyperconstricting
esponses. The stent implantation procedures were compa-
able between the BMS (Velocity) and the SES sites (Table 2).
oronary hyperconstricting responses to serotonin were also
oted at the proximal and distal edge segments of the SES
ite as compared with the BMS site, which was abolished by
ntracoronary pre-treatment with hydroxyfasudil (Figs. 7
nd 8). The histological analysis showed the higher score of
icrothrombus formation (SES 2.33  0.33, BMS 0.75 
.28) and of inflammatory responses (SES 5.00  1.30,
MS 0.70  0.12) in SES sites than in BMS sites (both
 0.01).
iscussion
he major findings of this study were: 1) paclitaxel in-
reased Rho-kinase expression and activity in hCASMCs
ammatory Responses in Pigs In Vivo
ries (B, E, H). Scale bars represent 1 mm (A, B) and 200 m (D, E, G, H),
ignificantly suppressed in the PES site (C), peristent microthrombus formation
significantly enhanced at the PES site compared with the BMS site (n  6d Infl
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I) were
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Coronary Hyperconstriction and DES-Enhanced Rho-Kinase December 8, 2009:2321–9n vitro; 2) PES enhanced coronary vasoconstricting
esponses to serotonin as compared with BMS in pigs
oth in vivo and in vitro; 3) the hyperconstrictive
esponses were abolished by hydroxyfasudil, a selective
Figure 5 PES Enhances Coronary Rho-Kinase Expression and A
Representative immunostainings of BMS-treated arteries (A, E, I), PES-treated arteries
sent 1 mm (A, B, E, F, I, J) and 200 m (C, G, K), respectively. Semiquantitative ana
subunit 1 (pMYPT1) (L) were expressed to a greater extent in the PES site compared
Figure 6 PES Causes Hypercontractions of Porcine Coronary A
Serotonin-induced contractions of isolated coronary rings without endothelium, wh
the edge of the PES site compared with the BMS site (A). In contrast, no differenc
not significant; other abbreviations as in Figure 2.ho-kinase inhibitor; 4) those functional alterations of
he coronary arteries were associated with enhanced
icrothrombus formation and inflammatory cell infiltra-
ion, where immunoreactivities for ROCK1, ROCK2,
y in Pigs In Vivo
, J), and magnified images of the PES-treated arteries (C, G, K). Scale bars repre-
howed that ROCK1 (D), ROCK2 (H), and phosphorylated myosin phosphatase target
e BMS site (n  6 each). Abbreviations as in Figures 1 and 2.
s In Vitro
ressed as percent contraction to 62 mmol/l KCl, were significantly enhanced at
noted at the control site (B). Results are expressed as mean  SEM. NS ctivit
(B, F
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December 8, 2009:2321–9 Coronary Hyperconstriction and DES-Enhanced Rho-Kinasend Rho-kinase activity (phospho-MYPT1) were in-
reased; and 5) SES also caused similar coronary hyper-
onstricting responses in vivo as did PES.
ES and Rho-kinase. Paclitaxel, a tubulin polymerizing
gent (31), is now widely used for the pharmacologic compo-
ent of DES because it inhibits VSMC proliferation and
igration in vitro (22) and suppresses neointimal thickening in
nimal models in vivo (32). The present result with
CASMCs provides new findings that paclitaxel significantly
nhances ROCK1 and ROCK2 messenger RNA expression
nd Rho-kinase activity at its clinically relevant concentration.
he previous studies showed that Rho guanine triphosphatases
ontrol organization of the actin cytoskeleton (33) and that
ho could be activated by paclitaxel, possibly through inter-
ering with microtubules or actin polymerization (34), suggest-
ng that paclitaxel may activate Rho-kinase in part by cytoskel-
tal reorganization.
Enhanced Rho-kinase activity plays a central role in the
athogenesis of coronary vasospasm (11). Intracoronary
dministration of fasudil or hydroxyfasudil (11), selective
ho-kinase inhibitors, markedly inhibits coronary vaso-
pasm in porcine models with various inflammatory stimuli
rocedural and Angiographic Findings,omparison Between BMS and SESTable 2 Procedural and Angiographic Findings,Comparison Between BMS and SES
BMS SES p Value
Control vessel diameter (mm) 2.69 0.12 2.58 0.24 0.24
Stent diameter (mm) 2.62 0.21 2.70 0.18 0.49
Stent length (mm) 19.7 1.1 19.2 1.3 0.77
Overstretch ratio 0.97 0.08 1.03 0.07 0.21
Maximum inflation pressure (atm) 10.8 1.1 12.0 0.0 0.15
alues are expressed as mean  SEM (n  6 each). Stent diameter was calculated by averaging
he diameters at the proximal edge, mid portion, and distal edge of the stented coronary artery.
verstretch ratio is the stent diameter divided by the control vessel diameter. Nominal pressure
as 8 atm for bare-metal stents (BMS) (Velocity, Johnson & Johnson, New Brunswick, New Jersey)
nd 12 atm for sirolimus-eluting stents (SES), respectively.
Figure 7 SES Enhances Coronary Vasoconstricting Responses
Representative left coronary angiograms under control condition (A), after intracor
serotonin with HF (300 g/kg intracoronary administration) (C). Pink lines indicate
of BMS implantation. Pink arrows indicate the proximal and distal edges of SES, a
and BMS are shown in the boxes (B). Abbreviations as in Figure 2.n vivo (13–18) and in humans (19,20). In the present
orcine model, serotonin-induced coronary hypercon-
triction was significantly enhanced at the PES as well as
he SES site as compared with the BMS site. This
nding was duplicated in organ chamber experiments
sing coronary rings without endothelium. Endothelial
unction was equally but modestly reduced at the PES
nd BMS sites in vivo. The previous study reported that
aclitaxel did not impair endothelium nitric oxide syn-
hase activity or nitric oxide release from coronary artery
ndothelial cells (35). Thus, in the present porcine
odel, the coronary hyperconstricting responses are
ainly caused by VSMC hypercontraction through a
ho-kinase–mediated mechanism rather than endothelial
ysfunction, a finding consistent with the previous stud-
es (27,36).
echanisms of DES-induced Rho-kinase activation. A
ES consists of 3 distinct components, including platform,
rug, and polymer. In the present study, a possible adverse
ffect of platform can be excluded because we used the same
latform and the procedural data were well comparable
etween the 2 stent sites. In the present study, neointimal
ormation was more suppressed and peristent microthrom-
us formation was more enhanced at the DES site. These
istological findings reflect antiproliferative effects of pacli-
axel on both VSMC and endothelial cells, leading to
elayed re-endothelialization and resultant thrombus for-
ation (37). Activated platelets may be involved in the
hrombus formation through Rho/Rho-kinase pathways by
eleasing serotonin and platelet-derived growth factors (11)
nd interactions with thrombin (38).
The present study also showed that inflammatory re-
ponses were accelerated at the DES site. These changes
ould be caused by a local hypersensitivity reaction to the
onbioabsorbing polymer used in DES (37). Indeed, we
ave previously shown that the expression of Rho-kinase
s In Vivo
serotonin (100 g/kg intracoronary administration) (B), and after intracoronary
ite of sirolimus-eluting stent (SES) implantation, and blue lines indicate the site
e arrows indicate those of BMS. Magnified images of the distal edge of SESin Pig
onary
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Coronary Hyperconstriction and DES-Enhanced Rho-Kinase December 8, 2009:2321–9tself is accelerated by inflammatory stimuli, such as angio-
ensin II and interleukin-1 beta, through protein kinase
/nuclear factor kappa beta pathway (39). Thus, it is
onceivable that DES-induced inflammatory responses also
nhance Rho-kinase activity with a resultant coronary hy-
erconstricting response and thrombus formation. Indeed,
n association with those changes, immunoreactivities of
OCK1, ROCK2, and phospho-MYPT1, a reliable marker
f Rho-kinase activity (29), were enhanced.
tudy limitations. First, we were unable to dissect the roles
f ROCK1 and ROCK2. Recently, it was reported that
OCK isoforms may have different roles in neointimal
ormation (40). Furthermore, the localization of Rho-kinase
ctivation and the role of other G-proteins (e.g., Rac-1)
emain to be examined in future studies. Second, the present
tudy was performed in normal juvenile pigs without pre-
xisting atherosclerotic coronary lesions. This might ex-
lain, at least in part, the discrepancy between the present
nimal study (normal vascular function at the distal seg-
ent) and the previous clinical study (coronary hypercon-
tricting responses even at the distal segment of DES-
mplanted arteries) (6). Finally, in the present study, we
sed intracoronary serotonin administration to examine
oronary vasomotor responses. In the clinical setting, ace-
ylcholine is now frequently used to provoke coronary
pasm. However, it has been reported that serotonin better
imics spontaneous vasospasm in humans than acetylcho-
Figure 8 SES Enhances Coronary Vasoconstricting Responses
Coronary vasoconstricting responses to intracoronary serotonin (5-HT) before and
and the control sites (B). The vasoconstricting responses are expressed as perce
istration). Results are expressed as mean  SEM. *p  0.05 versus control site.
stents; other abbreviations as in Figure 2.ine (41).onclusions
he present study suggests that the activated Rho-kinase
athway plays an important pathogenetic role in the DES-
nduced coronary hyperconstricting responses. Use of Rho-
inase inhibitors and other vasculoprotective agents (e.g.,
alcium-channel blockers and statins), in addition to devel-
ping innovative devices, may help to optimize the efficacy
nd safety of DES.
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